Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
Therapeutic targeting of “undruggable” MYC
V Llombart, MR Mansour - EBioMedicine, 2022 - thelancet.com
Summary c-MYC controls global gene expression and regulates cell proliferation, cell
differentiation, cell cycle, metabolism and apoptosis. According to some estimates, MYC is …
differentiation, cell cycle, metabolism and apoptosis. According to some estimates, MYC is …
MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - mdpi.com
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
Mutant p53 as a guardian of the cancer cell
F Mantovani, L Collavin, G Del Sal - Cell Death & Differentiation, 2019 - nature.com
Forty years of research have established that the p53 tumor suppressor provides a major
barrier to neoplastic transformation and tumor progression by its unique ability to act as an …
barrier to neoplastic transformation and tumor progression by its unique ability to act as an …
The role of p53 signaling in colorectal cancer
MC Liebl, TG Hofmann - Cancers, 2021 - mdpi.com
Simple Summary The transcription factor p53 is a crucial tumor suppressor that regulates
diverse cellular responses to protect against cancer development. Deactivating p53 …
diverse cellular responses to protect against cancer development. Deactivating p53 …
[HTML][HTML] Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to
current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and …
current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and …
A review of prognostic and predictive biomarkers in breast cancer
E Tarighati, H Keivan, H Mahani - Clinical and experimental medicine, 2023 - Springer
Breast cancer (BC) is a common cancer all over the world that affects women. BC is one of
the leading causes of cancer mortality in women, which today has decreased with the …
the leading causes of cancer mortality in women, which today has decreased with the …
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
C Dubiella, BJ Pinch, K Koikawa, D Zaidman… - Nature chemical …, 2021 - nature.com
The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and
inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an …
inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an …
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
K Sabapathy, DP Lane - Nature reviews Clinical oncology, 2018 - nature.com
TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated
gene across all cancer types. The presence of mutant p53 predisposes to cancer …
gene across all cancer types. The presence of mutant p53 predisposes to cancer …
Targeting transcription factors in cancer
AS Bhagwat, CR Vakoc - Trends in cancer, 2015 - cell.com
Transcription factors (TFs) are commonly deregulated in the pathogenesis of human cancer
and are a major class of cancer cell dependencies. Consequently, targeting of TFs can be …
and are a major class of cancer cell dependencies. Consequently, targeting of TFs can be …